Scarica l'app Stockscreener
1.37
10.00%
0.12
Adc Therapeutics Sa Borsa (ADCT) Ultime notizie
ADC Therapeutics (ADCT) CMO awarded 213,900 RSUs, raising holdings to 896,317 shares - Stock Titan
ADC Therapeutics (ADCT) grants 221,100 RSUs to Chief Legal Officer - Stock Titan
ADC Therapeutics (ADCT) grants CFO 203,700 RSUs as equity award - Stock Titan
ADC Therapeutics (ADCT) CEO receives 675,000 RSU equity award in Form 4 filing - Stock Titan
Executive retention awards approved at ADC Therapeutics (NYSE: ADCT) - Stock Titan
ADC Therapeutics Announces New Employee Inducement Grant - PR Newswire
ADC Therapeutics Completes Enrollment in LOTIS-7, Advancing ZYNLONTA-Glofitamab Combination in DLBCL - BioPharm International
ADC Therapeutics completes LOTIS-7 trial enrollment - grafa.com
ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study - marketscreener.com
ADC Therapeutics completes enrollment in LOTIS-7 trial - Investing.com
ADC Therapeutics completes enrollment in LOTIS-7 trial By Investing.com - Investing.com Nigeria
ADC Therapeutics ends enrollment in ZYNLONTA combo trial for lymphoma - Stock Titan
ADC Therapeutics updates trial strategy, shares react to oncology shift - AD HOC NEWS
ETFs Investing in ADC Therapeutics Ltd Stocks - TradingView
ADC Therapeutics SA(NYSE: ADCT) added to Russell 2000 Value Benchmark - marketscreener.com
ADC Therapeutics SA(NYSE: ADCT) added to Russell Microcap Value Benchmark Index - marketscreener.com
ADCT stock plunges on safety concerns despite positive lymphoma data - MSN
ADC Therapeutics SA(NYSE: ADCT) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
ADCT Q3 2020 Earnings Call - BigGo ファイナンス
ADC Therapeutics SA(NYSE: ADCT) added to Russell 3000E Value Benchmark - marketscreener.com
Enterprise value to revenue forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views - Yahoo Finance
Enterprise value to EBIT forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
Enterprise value to EBITDA forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
Price to earnings forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
ADCT News | ADC THERAPEUTICS SA (NYSE:ADCT) - ChartMill
ADC Therapeutics Ltd Actuals & Estimates (NYSE:ADCT) - TradingView
ADCT Forecast — Price Target — Prediction for 2027 - TradingView
ADC Therapeutics launches restructuring around ZYNLONTA - grafa.com
ADC Therapeutics Announces 17% Workforce Reduction and Strategic Reorganization to Boost ZYNLONTA® Growth and Regulatory Milestones - Minichart
Bronstein, Gewirtz & Grossman, LLC (ADCT) Investigation: Bronstei - The National Law Review
ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details - Stocktwits
ADC Therapeutics plans 17% workforce cut to save ~$10M annually, $3M one-time charges - TradingView
ADC Therapeutics (NYSE: ADCT) trims workforce 17% to back ZYNLONTA trials and extend cash runway - Stock Titan
ADC Therapeutics to cut 17% of workforce, save $10M annually - Investing.com Australia
ADC Therapeutics Announces Strategic Reorganization to Support Z - GuruFocus
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities – Company AnnouncementFT.com - Financial Times
ADC Therapeutics Cuts 17% of Workforce, Targets $10 Million in Annual Savings - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Shareholders to Inquire about Securities Investigation | NYSE:ADCT | Press Release - Stockhouse
Tango Therapeutics Appoints New Board Member - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Shareholders to Connect - ACCESS Newswire
2026-06-22 | Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Shareholders to Connect | NYSE:ADCT | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Why ADC Therapeutics’ loncastuximab tesirine is still on oncologists’ radar - AD HOC NEWS
ADC Therapeutics falls on confirmatory trial data for lymphoma therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - PR Newswire
ADC Therapeutics SA (ADCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ADC Therapeutics SA (ADCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ADC Therapeutics SA (ADCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ADC Therapeutics SA (ADCT) Institutional Confidence - TradingKey
ADC Therapeutics SA (ADCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ADC Therapeutics SA (ADCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ADC Therapeutics SA (ADCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ADC Therapeutics SA (ADCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ADC Therapeutics SA (ADCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why ZYNLONTA still matters for ADC Therapeutics in a tightening lymphoma market - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Investors to Connect - ACCESS Newswire
0.17%
1.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):